Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viatris Inc (NQ: VTRS )

9.140 -0.200 (-2.14%)
Official Closing Price Updated: 4:15 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,722,869
Open 9.320
Bid (Size) 9.140 (1)
Ask (Size) 9.230 (2)
Prev. Close 9.340
Today's Range 9.110 - 9.340
52wk Range 8.740 - 12.40
Shares Outstanding 1,212,301,241
Dividend Yield 5.25%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
7 Low P/E Stocks Poised to Rebound
Each of these seven low P/E value stocks trades for under 10 times earnings, but could rise to a much higher valuation as sentiment improves. 
Via InvestorPlace
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and... 
Via Talk Markets

Performance

YTD
-19.68%
-19.68%
1 Month
+3.39%
+3.39%
3 Month
-16.91%
-16.91%
6 Month
-0.44%
-0.44%
1 Year
-17.36%
-17.36%

More News

Read More
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Recap: Viatris Q3 Earnings
Via Benzinga
3 Large-Cap Stocks to Buy Trading Below Book Value
Via InvestorPlace
Topics Stocks
Exposures US Equities
2 Top Value Stocks to Buy in October
Via The Motley Fool
Viatris Stock: Bear vs. Bull
Via The Motley Fool
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
Via The Motley Fool
Earnings Scheduled For November 7, 2023
Via Benzinga
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
Via The Motley Fool
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?
Via The Motley Fool
2 Healthcare Dividend Stocks You'd Regret Not Buying on the Dip
Via The Motley Fool
Obesity Drug Wegovy's Triumph to Catapult Novo Holdings In Golden Era Of Wealth Boost
Via Benzinga
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
Via Benzinga
Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Viatris Stock Bounds Higher As Divestitures Reach Nearly $7 Billion
Via Investor's Business Daily
Viatris Phase 1 Asset Divestiture Story: Plans To Sell Certain OTC Products, Women's Healthcare Business & More
Via Benzinga
Could Viatris Stock Help You Become a Millionaire?
Via The Motley Fool
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report
Via Benzinga
NASDAQ: VTRS Shareholder Notice Investigation over Potential Wrongdoing by Certain Directors of Viatris Inc.
Via SBWire
'Stocks In Monopolistic Bull Market': Wall Street Analyst Contemplates A Bright Future For Next Phase
Via Benzinga
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks
Via The Motley Fool
3 Pharmaceutical Stocks That Are Too Cheap to Ignore
Via The Motley Fool
CVS Health Just Created a New Problem For Viatris. Here's What You Need to Know
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback